君实生物 · Junshi Biosciences

Partnering

Partnering Overview

We work with partners to advance research programs and bring medicines to patients in additional markets.

Research at Junshi Biosciences

Areas for Collaboration

Licensing

Discuss rights to a specific asset, indication or territory.

Commercialization

Explore distribution, market access and regional commercial partnerships.

Co-development

Discuss shared clinical development plans for a candidate or indication.

Manufacturing

Discuss supply and manufacturing requirements with the relevant teams.

Research

Explore a research collaboration around a target, modality or program.

What We Bring

Discovery and development

Innovation centers in China and the United States support drug discovery and clinical development.

Manufacturing

Two commercial facilities in China support biologics production and clinical supply.

Regional partnerships

Territory-specific collaborations support the development and commercialization of medicines such as toripalimab.

Selected Partners

Explore selected announced collaborations, including their original scope and announcement year.

Lilly

2020 · Announced agreement

Agreed to collaborate on neutralizing antibodies for COVID-19, including the candidate later named etesevimab.

Read the announcement

Coherus

2021 · Announced agreement

Announced a collaboration for toripalimab development and commercialization in the United States and Canada.

Read the announcement

LEO Pharma

2025 · Announced agreement

Agreed to distribute and market toripalimab in European territories. TopAlliance Biosciences Europe retained the marketing authorization.

Read the announcement

Dr. Reddy’s Laboratories

2023 · Announced agreement

Announced a collaboration to develop and commercialize toripalimab in India, South Africa and selected Latin American markets.

Read the announcement

Hikma Pharmaceuticals

2022 · Announced agreement

Licensed rights to develop and commercialize toripalimab in specified Middle East and North Africa markets.

Read the announcement

Business Development Contact

For partnering inquiries, call our Shanghai headquarters and ask for Business Development.

+86 21 6105 8800